Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
Bes F, Hofman W, Schuur J, et al
Lumertz FS, Kestering-Ferreira E, Orso R, Creutzberg KC, Tractenberg SG, Stocchero BA, et al
UHCs 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity
Almost a third of people treated with the higher dose had a bodyweight reduction of more than 25%, and 83.4% of patients with prediabetes at the start of the trial had returned to normal blood sugar levels by the end of the trial, compared to 73.8% for the standard dose and 36.6% for the placebo group
